Multi-center safety and efficacy study of a negative-pressure intraoral device in obstructive sleep apnea

Background: Intraoral devices, with or without negative oral pressure, can stabilize the oropharynx and reduce obstructive sleep apneas. We tested the hypothesis that treatment with the iNAP (R) Sleep Therapy System, which applies negative oral pressure through an intra-oral appliance, would reduce the severity of obstructive sleep apnea in a multi -center, prospective, first -night -randomized -order cross -over study. Methods/patients: 130 patients fulfilled the entry criteria (age <75, AHI 15 -55, BMI <33), and 63 entered the primary endpoint cohort (Total Sleep Time >= 4 h/night on the baseline polysomnogram and an oral negative vacuum time maintained by iNAP (R) >= 4 h/night and total sleep time >= 4 h/night during the first treatment study). 54 patients completed a second treatment sleep study at least 28 days after the first sleep study. Results: Among the primary endpoint cohort (n = 63, age = 53.2 +/- 11.3, BMI = 27.1 +/- 2.8), 33 patients (52 %; 95 % confidence interval = 40% -64 %, p < 0.001) responded to iNAP treatment according to the Sher criteria ( >50 % reduction in AHI and an AHI <= 20 events/hr). The average oxy-hemoglobin saturation increased by 1 -2%, and the average percent oxygen desaturation decreased (was less severe) by 1 % while using the iNAP device. The incidence of adverse events, all self -limited, was low. The reduction in the apnea-hypopnea index was durable over the 28 -day study. Patients used iNAP on average 5.6 h per night during the study period. Conclusion: The iNAP (R) Sleep Therapy System achieved a durable benefit in more than half the patients with moderate to severe obstructive sleep apnea and may be considered in patients who object to or failed continuous positive airway pressure. Clinical trial registration: ClinicalTrials.gov Identifier: NCT02698059.